GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evoke Pharma Inc (STU:EV00) » Definitions » EV-to-EBITDA

Evoke Pharma (STU:EV00) EV-to-EBITDA : -0.58 (As of May. 16, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Evoke Pharma EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Evoke Pharma's enterprise value is €3.91 Mil. Evoke Pharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €-6.77 Mil. Therefore, Evoke Pharma's EV-to-EBITDA for today is -0.58.

The historical rank and industry rank for Evoke Pharma's EV-to-EBITDA or its related term are showing as below:

STU:EV00' s EV-to-EBITDA Range Over the Past 10 Years
Min: -6.71   Med: -0.55   Max: 0.3
Current: -0.58

During the past 13 years, the highest EV-to-EBITDA of Evoke Pharma was 0.30. The lowest was -6.71. And the median was -0.55.

STU:EV00's EV-to-EBITDA is ranked worse than
100% of 707 companies
in the Drug Manufacturers industry
Industry Median: 14.79 vs STU:EV00: -0.58

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-16), Evoke Pharma's stock price is €0.428. Evoke Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-2.162. Therefore, Evoke Pharma's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Evoke Pharma EV-to-EBITDA Historical Data

The historical data trend for Evoke Pharma's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evoke Pharma EV-to-EBITDA Chart

Evoke Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.78 -5.05 -1.72 -0.55 -0.52

Evoke Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.55 -0.41 -0.48 -0.52 -0.52

Competitive Comparison of Evoke Pharma's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Evoke Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evoke Pharma's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evoke Pharma's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Evoke Pharma's EV-to-EBITDA falls into.



Evoke Pharma EV-to-EBITDA Calculation

Evoke Pharma's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=3.914/-6.765
=-0.58

Evoke Pharma's current Enterprise Value is €3.91 Mil.
Evoke Pharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-6.77 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Evoke Pharma  (STU:EV00) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Evoke Pharma's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.428/-2.162
=At Loss

Evoke Pharma's share price for today is €0.428.
Evoke Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.162.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Evoke Pharma EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Evoke Pharma's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Evoke Pharma (STU:EV00) Business Description

Traded in Other Exchanges
Address
420 Stevens Avenue, Suite 370, Solana Beach, CA, USA, 92075
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.

Evoke Pharma (STU:EV00) Headlines

No Headlines